The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer
Open accessAbstract
Increased androgen receptor (AR) activity drives therapeutic resistance in advanced prostate cancer. The most common resistance mechanism is amplification of this locus presumably targeting the AR gene. Here, we identify and characterize a somatically acquired AR enhancer located 650 kb centromeric to the AR. Systematic perturbation of this enhancer using genome editing decreased proliferation by suppressing AR levels. Insertion of an additional copy of this region sufficed to increase proliferation under low androgen conditions and to decrease sensitivity to enzalutamide. Epigenetic data generated in localized prostate tumors and benign specimens support the notion that this region is a developmental enhancer. Collectively, these observations underscore the importance of epigenomic profiling in primary specimens and the value of deploying genome editing to functionally characterize noncoding elements. More broadly, this work identifies a therapeutic vulnerability for targeting the AR and emphasizes the importance of regulatory elements as highly recurrent oncogenic drivers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We and other groups have identified tumor alterations that reactivate AR signaling during treatment with an ARSI2,22–29.”
From Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer (2025) · cites this paper as [24]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These mechanisms of resistance include AR gene amplification22,23, AR enhancer amplification2,24,25, AR mutation26, AR genomic structural rearrangements27, AR splice variants28 and polymorphisms in androgen metabolism genes29.”
From Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer (2025) · cites this paper as [24]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.
Langmead, B., Trapnell, C., Pop, M., & Salzberg, S. L. (2009) · Genome Biology · doi:10.1186/gb-2009-10-3-r25 · Cited by 21,849
Model-based Analysis of ChIP-Seq (MACS)
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386
An integrated encyclopedia of DNA elements in the human genome
The ENCODE Project Consortium (2012) · Nature · doi:10.1038/nature11247 · Cited by 18,072
The language of covalent histone modifications
Strahl, B. D., & Allis, C. D. (2000) · Nature · doi:10.1038/47412 · Cited by 8,679
Topological domains in mammalian genomes identified by analysis of chromatin interactions
Dixon, J. R., Selvaraj, S., Yue, F., Kim, A., Li, Y., Shen, Y., Hu, M., Liu, J. S., & Ren, B. (2012) · Nature · doi:10.1038/nature11082 · Cited by 6,829
Integrative analysis of 111 reference human epigenomes
Roadmap Epigenomics Consortium, Kundaje, A., Meuleman, W., Ernst, J., Bilenky, M., Yen, A., Heravi-Moussavi, A., Kheradpour, P., Zhang, Z., Wang, J., et al. (2015) · Nature · doi:10.1038/nature14248 · Cited by 6,368
Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications
Krueger, F., & Andrews, S. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr167 · Cited by 5,275
Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9
Doench, J. G., Fusi, N., Sullender, M., Hegde, M., Vaimberg, E. W., Donovan, K. F., Smith, I., Tothova, Z., Wilen, C., Orchard, R., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3437 · Cited by 4,637
Histone H3K27ac separates active from poised enhancers and predicts developmental state
Creyghton, M. P., Cheng, A. W., Welstead, G. G., Kooistra, T., Carey, B. W., Steine, E. J., Hanna, J., Lodato, M. A., Frampton, G. M., Sharp, P. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016071107 · Cited by 4,302
Flagged first, then by citations
Cited by
Sorted by citations
Cistrome Data Browser: expanded datasets and new tools for gene regulatory analysis
Zheng, R., Wan, C., Mei, S., Qin, Q., Wu, Q., Sun, H., Chen, C.-H., Brown, M. A., Zhang, X., Meyer, C. A., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky1094 · Cited by 908
Protein degraders enter the clinic — a new approach to cancer therapy
Chirnomas, D., Hornberger, K. R., & Crews, C. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00736-3 · Cited by 658
Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer
Sharp, A., Coleman, I. M., Yuan, W., Sprenger, C. C. T., Dolling, D. I., Rodrigues, D. N., Russo, J. W., Figueiredo, I., Bertan, C. M., Seed, G., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci122819 · Cited by 403
Armstrong, A. J., Halabi, S., Luo, J., Nanus, D. M., Giannakakou, P., Szmulewitz, R. Z., Danila, D. C., Healy, P. N., Anand, M., Rothwell, C., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01731 · Cited by 371
Viswanathan, S. R., Ha, G., Hoff, A. M., Wala, J. A., Carrot-Zhang, J., Whelan, C. W., Haradhvala, N. J., Freeman, S. S., Reed, S. C., Rhoades, J., et al. (2018) · Cell · doi:10.1016/j.cell.2018.05.036 · Cited by 365
The DNA methylation landscape of advanced prostate cancer
Zhao, S. G., Chen, W. S., Li, H., Foye, A., Zhang, M., Sjöström, M., Aggarwal, R. R., Playdle, D., Liao, A., Alumkal, J. J., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0648-8 · Cited by 357
Functional Enhancers Shape Extrachromosomal Oncogene Amplifications
Morton, A. R., Dogan-Artun, N., Faber, Z. J., MacLeod, G. D. A. H., Bartels, C. F., Piazza, M. S., Allan, K. C., Mack, S. C., Wang, X., Gimple, R. C., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.039 · Cited by 336
Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer
Xiao, L., Parolia, A., Qiao, Y., Bawa, P., Eyunni, S., Mannan, R., Carson, S. E., Chang, Y., Wang, X., Zhang, Y., et al. (2021) · Nature · doi:10.1038/s41586-021-04246-z · Cited by 324
Prostate cancer reactivates developmental epigenomic programs during metastatic progression
Pomerantz, M. M., Qiu, X., Zhu, Y., Takeda, D. Y., Pan, W., Baca, S. C., Gusev, A., Korthauer, K. D., Severson, T., Ha, G., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0664-8 · Cited by 274
Self-citationTumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer
Zhang, Z., Karthaus, W. R., Lee, Y. S., Gao, V. R., Wu, C., Russo, J. W., Liu, M., Mota, J. M., Abida, W. M., Linton, E. L., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.06.005 · Cited by 260
Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications
Aurilio, G., Cimadamore, A., Roberta Mazzucchelli, A., Antonio Lopez-beltran, B., Verri, E., Scarpelli, M., Massari, F., Liang Cheng, C., Santoni, M., & Montironi, R. (2020) · Cells · doi:10.3390/cells9122653 · Cited by 283
Enhancer RNA m6A methylation facilitates transcriptional condensate formation and gene activation
Lee, J.-H., Wang, R., Xiong, F., Krakowiak, J., Liao, Z., Nguyen, P. T.-M., Moroz, E., Shao, J., Zhu, X., Bolt, M. J., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.07.024 · Cited by 281
Towards precision oncology in advanced prostate cancer
Ku, S., Gleave, M. E., & Beltran, H. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0237-8 · Cited by 230
van Dessel, L. F., van Riet, J., Smits, M., Zhu, Y., Hamberg, P., van der Heijden, M. S., Bergman, A. M., van Oort, I. M., de Wit, R., Voest, E. E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13084-7 · Cited by 214
Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
Feng, Q. F., & He, B. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00858 · Cited by 202
Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer
Herberts, C., Annala, M., Sipola, J., Ng, S. W. S., Chen, X. E., Nurminen, A., Korhonen, O. V., Munzur, A. D., Beja, K., Schönlau, E., et al. (2022) · Nature · doi:10.1038/s41586-022-04975-9 · Cited by 193
Targeting the Androgen Signaling Axis in Prostate Cancer
Dai, C. S., Dehm, S. M., & Sharifi, N. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00433 · Cited by 182
Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer
Baca, S. C., Takeda, D. Y., Seo, J.-H., Hwang, J. H., Ku, S., Arafeh, R., Arnoff, T. E., Agarwal, S., Bell, C. A., O’Connor, E. P., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22139-7 · Cited by 163
Self-citationCellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications
Testa, U., Castelli, G., & Pelosi, E. (2019) · Medicines · doi:10.3390/medicines6030082 · Cited by 168
Rubin, M. A., Bristow, R. G., Thienger, P., Dive, C., & Imielinski, M. B. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.10.033 · Cited by 140
Androgen receptor (AR) heterogeneity in prostate cancer and therapy resistance
Jamroze, A., Chatta, G. S., & Tang, D. G. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.06.006 · Cited by 140
Rhie, S. K., Perez, A. A., Lay, F. D., Schreiner, S., Shi, J., Polin, J., & Farnham, P. (2019) · Nature Communications · doi:10.1038/s41467-019-12079-8 · Cited by 130
Liquid biopsy epigenomic profiling for cancer subtyping
Baca, S. C., Seo, J.-H., Davidsohn, M. P., Fortunato, B. J., Semaan, K., Sotudian, S., Lakshminarayanan, G., Dióssy, M., Qiu, X., Zarif, T. E., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02605-z · Cited by 137
Self-citationBiological Evolution of Castration-resistant Prostate Cancer
Davies, A., Conteduca, V., Zoubeidi, A., & Beltran, H. (2019) · European Urology Focus · doi:10.1016/j.euf.2019.01.016 · Cited by 126
A High-Resolution Map of Human Enhancer RNA Loci Characterizes Super-enhancer Activities in Cancer
Chen, H., & Liang, H. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.020 · Cited by 125
Computational analysis of cancer genome sequencing data
Cortés‐Ciriano, I., Gulhan, D., Lee, J. J.-K., Melloni, G. E. M., & Park, P. J. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00431-y · Cited by 118
Wang, Y., Chen, J., Wu, Z., Ding, W., Gao, S., Gao, Y., & Xu, C. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15300 · Cited by 117
Structural variations in cancer and the 3D genome
Dubois, F. P. B., Sidiropoulos, N., Weischenfeldt, J., & Beroukhim, R. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00488-9 · Cited by 112
Zhu, Y., Dalrymple, S. L., Coleman, I. M., Zheng, S. L., Xu, J., Hooper, J. E., Antonarakis, E. S., Marzo, A. M. D., Meeker, A. K., Nelson, P. S., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01479-6 · Cited by 107
Annala, M., Taavitsainen, S., Khalaf, D. J., Vandekerkhove, G. R., Beja, K., Sipola, J., Warner, E. W., Herberts, C., Wong, A., Fu, S. Y. F., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1625 · Cited by 95
Snyder, L. B., Neklesa, T. K., Willard, R. R., Gordon, D., Pizzano, J., Vitale, N., Robling, K., Dorso, M. A., Moghrabi, W. N., Landrette, S. F., et al. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0655 · Cited by 104
Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models
Sugawara, T., Baumgart, S. J., Nevedomskaya, E., Reichert, K., Steuber, H., Lejeune, P., Mumberg, D., & Haendler, B. (2019) · International Journal of Cancer · doi:10.1002/ijc.32242 · Cited by 95
Targeting Nuclear Receptors with PROTAC degraders
Flanagan, J. J., & Neklesa, T. K. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.110452 · Cited by 98
A noncanonical AR addiction drives enzalutamide resistance in prostate cancer
He, Y., Wei, T., Ye, Z., Orme, J. J., Lin, D., Sheng, H., Fazli, L., Karnes, R. J., Jiménez, R. E., Wang, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21860-7 · Cited by 94
Illuminating the noncoding genome in cancer
Zhang, X., & Meyerson, M. M. (2020) · Nature Cancer · doi:10.1038/s43018-020-00114-3 · Cited by 86
Mapping genomic and epigenomic evolution in cancer ecosystems
Ushijima, T., Clark, S. J., & Tan, P. B. O. (2021) · Science · doi:10.1126/science.abh1645 · Cited by 89
The roles of epigenetics in cancer progression and metastasis
Chen, J. F.-Y., & Yan, Q. (2021) · Biochemical Journal · doi:10.1042/bcj20210084 · Cited by 89
Linder, S., Hoogstraat, M., Stelloo, S., Eickhoff, N., Schuurman, K. G., de Barros, H. A., Alkemade, M., Bekers, E. M., Severson, T., Sanders, J., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0576 · Cited by 83
Self-citationRathkopf, D. E., Patel, M. R., Choudhury, A. D., Rasco, D. W., Lakhani, N. J., Hawley, J. E., Srinivas, S., Aparicio, A. M., Narayan, V., Runcie, K. D., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.09.005 · Cited by 89
Androgen Receptor-Dependent Mechanisms Mediating Drug Resistance in Prostate Cancer
Ehsani, M., David, F. O., & Baniahmad, A. (2021) · Cancers · doi:10.3390/cancers13071534 · Cited by 83
Rational optimization of a transcription factor activation domain inhibitor
Basu, S., Martínez-Cristóbal, P., Frigolé-Vivas, M., Pesarrodona, M., Lewis, M., Szulc, E., Bañuelos, C. A., Sánchez-Zarzalejo, C., Bielskutė, S., Zhu, J., et al. (2023) · Nature Structural & Molecular Biology · doi:10.1038/s41594-023-01159-5 · Cited by 83
“In addition, 3D HNCO and HNCA experiments were acquired for two 15N,13C double labeled AR AD (1-558) samples (25 μM and 100 μM) dissolved in NMR buffer.”
Targeting DNA Damage Response in Prostate and Breast Cancer
Wengner, A. M., Scholz, A., & Haendler, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218273 · Cited by 81
Aggarwal, R. R., Quigley, D. A., Huang, J., Zhang, L., Beer, T. M., Rettig, M. B., Reiter, R. E., Gleave, M. E., THOMAS, G. V., Foye, A., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-1101 · Cited by 80
Li, M., Liu, M., Han, W., Wang, Z., Han, D. G., Patalano, S. C., Macoska, J. A., Balk, S. P., He, H. H., Corey, E., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-2433 · Cited by 80
Androgen receptor and MYC equilibration centralizes on developmental super-enhancer
Guo, H., Wu, Y., Nouri, M., Spisák, S., Russo, J. W., Sowalsky, A. G., Pomerantz, M. M., Wei, Z., Korthauer, K. D., Seo, J.-H., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27077-y · Cited by 77
Self-citationAccelerating precision medicine in metastatic prostate cancer
Mateo, J., McKay, R. R., Abida, W. M., Aggarwal, R. R., Alumkal, J. J., Alva, A. S., Feng, F. Y.-C., Gao, X. Y., Graff, J. N., Hussain, M., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00141-0 · Cited by 76
Kim, D., Sun, D., Storck, W. K., Leng, K. W., Jenkins, C., Coleman, D. J., Sampson, D., Guan, X., Kumaraswamy, A., Rodansky, E. S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4968 · Cited by 73
Hwang, J. H., Seo, J.-H., Beshiri, M. L., Wankowicz, S. A. M., Liu, D., Cheung, A. T. M., Li, J., Qiu, X., Hong, A. L., Botta, G., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.068 · Cited by 68
Self-citationNoncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer
Zhou, S., Hawley, J. R., Soares, F., Grillo, G., Teng, M., Tonekaboni, S. A. M., Hua, J. T., Kron, K. J., Mazrooei, P., Ahmed, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14318-9 · Cited by 69
Molecular mechanisms and genetic alterations in prostate cancer: From diagnosis to targeted therapy
Fontana, F., Anselmi, M., & Limonta, P. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215619 · Cited by 68
Ghildiyal, R., Sawant, M., Renganathan, A., Mahajan, K. N., Kim, E. H., Luo, J., Dang, H. X., Maher, C. A., Feng, F. Y.-C., & Mahajan, N. P. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3845 · Cited by 67
A Practical Guide for Structural Variation Detection in the Human Genome
Yang, L. (2020) · Current Protocols in Human Genetics · doi:10.1002/cphg.103 · Cited by 66
Androgen receptor-binding sites are highly mutated in prostate cancer
Morova, T., McNeill, D. R., Lallous, N., Gönen, M., Dalal, K., Wilson, D. M., Gürsoy, A., Keskin, Ö., & Lack, N. A. (2020) · Nature Communications · doi:10.1038/s41467-020-14644-y · Cited by 65
Adelaiye-Ogala, R. M., Gryder, B. E., Nguyen, Y. T. M., Alilin, A. N., Grayson, A. R., Bajwa, W., Jansson, K. H., Beshiri, M. L., Agarwal, S., Rodriguez-Nieves, J. A., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0936 · Cited by 58
The landscape of RNA polymerase II–associated chromatin interactions in prostate cancer
Ramanand, S. G., Chen, Y., Yuan, J., Daescu, K., Lambros, M. B. K., Houlahan, K. E., Carreira, S., Yuan, W., Baek, G., Sharp, A., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci134260 · Cited by 54
Clinical Applications of Liquid Biopsy in Prostate Cancer: From Screening to Predictive Biomarker
Ionescu, F., Zhang, J., & Wang, L. (2022) · Cancers · doi:10.3390/cancers14071728 · Cited by 49
Burris, T. P., de Vera, I. M. S., Côté, I., Flaveny, C. A., Wanninayake, U. S., Chatterjee, A., Walker, J. K., Steinauer, N., Zhang, J., Coons, L. A., et al. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000436 · Cited by 54
Targeting the androgen receptor and overcoming resistance in prostate cancer
Einstein, D. J., Arai, S., & Balk, S. P. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000520 · Cited by 50
Labrecque, M. P., Brown, L. G., Coleman, I. M., Lakely, B., Brady, N. J., Lee, J. K., Nguyen, H. M., Li, D., Hanratty, B. P., Haffner, M. C., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0307 · Cited by 48
Androgen Receptor-Mediated Transcription in Prostate Cancer
Özturan, D., Morova, T., & Lack, N. A. (2022) · Cells · doi:10.3390/cells11050898 · Cited by 51
H3K27ac HiChIP in prostate cell lines identifies risk genes for prostate cancer susceptibility
Giambartolomei, C., Seo, J.-H., Schwarz, T., Freund, M. K., Johnson, R., Spisák, S., Baca, S. C., Gusev, A., Mancuso, N., Paşaniuc, B., et al. (2021) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2021.11.007 · Cited by 49
Self-citationZhou, R. W., Xu, J., Martin, T. C., Zachem, A. L., He, C., Ozturk, S., Demircioğlu, D., Bansal, A., Trotta, A. P., Giotti, B., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33377-8 · Cited by 49
Guo, L., Li, J., Zeng, H., Guzman, A. G., Li, T., Lee, M., Zhou, Y., Goodell, M. A., STEPHAN, C. C., Davies, P. J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14604-6 · Cited by 47
Future directions for precision oncology in prostate cancer
Mizuno, K., & Beltran, H. (2022) · The Prostate · doi:10.1002/pros.24354 · Cited by 49
The Role of Large Neutral Amino Acid Transporter (LAT1) in Cancer
Lu, X. (2019) · Current Cancer Drug Targets · doi:10.2174/1568009619666190802135714 · Cited by 46
Rodríguez, Y., Unno, K., Truica, M. I., Chalmers, Z. R., Yoo, Y. A., Vatapalli, R. J., Sagar, V., Yu, J., Lysy, B., Hussain, M., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3565 · Cited by 48
Liu, Y., Wu, Z., Zhou, J. R., Ramadurai, D. K. A., Mortenson, K. L., Aguilera-Jimenez, E., Yan, Y., Yang, X., Taylor, A. M., Varley, K. E., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27055-4 · Cited by 44
Zhao, S. G., Bootsma, M., Zhou, S., Shrestha, R., Moreno-Rodriguez, T., Lundberg, A., Pan, C., Arlidge, C., Hawley, J. R., Foye, A., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01826-3 · Cited by 42
Resistance to Antiandrogens in Prostate Cancer: Is It Inevitable, Intrinsic or Induced?
Maitland, N. J. (2021) · Cancers · doi:10.3390/cancers13020327 · Cited by 44
The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approaches
Labrecque, M. P., Alumkal, J. J., Coleman, I. M., Nelson, P. S., & Morrissey, C. M. (2021) · Endocrine Related Cancer · doi:10.1530/erc-21-0002 · Cited by 44
Germain, L., Lafront, C., Paquette, V., Neveu, B., Paquette, J., Pouliot, F., & Audet‐Walsh, É. (2023) · Nature Reviews Urology · doi:10.1038/s41585-023-00726-1 · Cited by 47
Tang, S., Sethunath, V., Metaferia, N. Y., Nogueira, M. F., Gallant, D. S., Garner, E. R., Lairson, L. A., Penney, C. M., Li, J., Gelbard, M. K., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110417 · Cited by 42
Self-citationBeyes, S., Bediaga, N. G., & Zippo, A. (2021) · Cancers · doi:10.3390/cancers13194969 · Cited by 44
Walavalkar, K., Saravanan, B., Singh, A. K., Jayani, R. S., Nair, A., Farooq, U., Islam, Z., Soota, D., Mann, R., Shivaprasad, P. V., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17325-y · Cited by 42
Self-citationRecent Discoveries in the Androgen Receptor Pathway in Castration-Resistant Prostate Cancer
Obinata, D., Lawrence, M. G., Takayama, K., Choo, N., Risbridger, G. P., Takahashi, S., & Inoue, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.581515 · Cited by 44
Kukkonen, K., Taavitsainen, S., Huhtala, L., Uusi-Mäkelä, J., Granberg, K. J., Nykter, M., & Urbanucci, A. (2021) · Cancers · doi:10.3390/cancers13133325 · Cited by 47
Maekawa, S., Takata, R., & Obara, W. (2024) · Cancers · doi:10.3390/cancers16030523 · Cited by 49
Darolutamide antagonizes androgen signaling by blocking enhancer and super‐enhancer activation
Baumgart, S. J., Nevedomskaya, E., Lesche, R., Newman, R., Mumberg, D., & Haendler, B. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12693 · Cited by 42
Zhang, L., Li, W., Parvin, R., Wang, X., Fan, Q., & Ye, F. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202207879 · Cited by 39
Miyahira, A. K., Sharp, A., Ellis, L., Jones, J. C., Kaochar, S., Larman, H. B., Quigley, D. A., Ye, H., Simons, J. W., Pienta, K. J., et al. (2019) · The Prostate · doi:10.1002/pros.23934 · Cited by 40
Post-Translational Modifications That Drive Prostate Cancer Progression
Samaržija, I. (2021) · Biomolecules · doi:10.3390/biom11020247 · Cited by 41
Larsson, P., Khaja, A. S. S., Semenas, J., Wang, T., Sarwar, M., Dizeyi, N., Simoulis, A., Hedblom, A., Wai, S. N., Ødum, N., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32607 · Cited by 39
Functional mapping of androgen receptor enhancer activity
Huang, C.-C. F., Lingadahalli, S., Morova, T., Özturan, D., Hu, E., Yu, I. P. L., Linder, S., Hoogstraat, M., Stelloo, S., Sar, F., et al. (2021) · Genome biology · doi:10.1186/s13059-021-02339-6 · Cited by 36
Exploring androgen receptor signaling pathway in prostate cancer: A path to new discoveries
Obinata, D., Takayama, K., Inoue, S., & Takahashi, S. (2024) · International Journal of Urology · doi:10.1111/iju.15424 · Cited by 38
Unlocking ferroptosis in prostate cancer — the road to novel therapies and imaging markers
Cao, P. H. A., Dominic, A., Lujan, F. E., Senthilkumar, S., Bhattacharya, P. K., Frigo, D. E., & Subramani, E. (2024) · Nature Reviews Urology · doi:10.1038/s41585-024-00869-9 · Cited by 43
Lü, X., Keo, V., Cheng, I., Xie, W., Gritsina, G., Wang, J., Lu, L., Shiau, C.-K., He, Y., Jin, Q., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02265-4 · Cited by 36
Revisiting 3D chromatin architecture in cancer development and progression
Feng, Y., & Pauklin, S. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa747 · Cited by 36
Mitsiades, N., & Kaochar, S. (2021) · Endocrine Related Cancer · doi:10.1530/erc-21-0098 · Cited by 39
Molecular underpinnings of enzalutamide resistance
Preković, S., den Broeck, T. V., Linder, S., van Royen, M. E., Houtsmuller, A. B., Handle, F., Joniau, S., Zwart, W. T., & Claessens, F. (2018) · Endocrine Related Cancer · doi:10.1530/erc-17-0136 · Cited by 37
Kita, Y., Goto, T., Akamatsu, S., Yamasaki, T., Inoue, T., Ogawa, O., & Kobayashi, T. (2018) · Cancers · doi:10.3390/cancers10100345 · Cited by 40
ACK1–AR and AR–HOXB13 signaling axes: epigenetic regulation of lethal prostate cancers
Kim, E. H., Cao, D., Mahajan, N. P., Andriole, G. L., & Mahajan, K. N. (2020) · NAR Cancer · doi:10.1093/narcan/zcaa018 · Cited by 37
Targeting histone H2B acetylated enhanceosomes via p300/CBP degradation in prostate cancer
Luo, J., Chen, Z., Qiao, Y., Tien, J. C.-Y., Young, E., Mannan, R., Mahapatra, S., Bhattacharyya, R., Xiao, L., He, T., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02336-6 · Cited by 39
Androgen receptor enhancer usage and the chromatin regulatory landscape in human prostate cancers
Stelloo, S., Bergman, A. M., & Zwart, W. T. (2019) · Endocrine Related Cancer · doi:10.1530/erc-19-0032 · Cited by 37
Resistance to second generation antiandrogens in prostate cancer: pathways and mechanisms
Verma, S., Prajapati, K. S., Kushwaha, P. P., Shuaib, M., Singh, A. K., Kumar, S., & Gupta, S. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.45 · Cited by 37
Pinto, F., Dibitetto, F., Ragonese, M., & Bassi, P. (2022) · Medical Sciences · doi:10.3390/medsci10020025 · Cited by 34
Genome-guided discovery of cancer therapeutic targets
Konda, P., Garinet, S., Allen, E. M. V., & Viswanathan, S. R. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112978 · Cited by 36
The androgen receptor is a therapeutic target in desmoplastic small round cell sarcoma
Lamhamedi-Cherradi, S.-E., Maitituoheti, M., Menegaz, B. A., Krishnan, S., Vetter, A. M., Camacho, P. E., Wu, C.-C., Beird, H. C., Porter, R. W., Ingram, D. R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30710-z · Cited by 35
Zivanovic, A., Miller, J. T., Munro, S. A., Knutson, T. P., Li, Y., Passow, C. N., Simonaitis, P., Lynch, M., Oseth, L., Zhao, S. G., et al. (2023) · NAR Cancer · doi:10.1093/narcan/zcad045 · Cited by 35
Anselmino, N., Labanca, E., Shepherd, P. D. A., Dong, J., Yang, J., Song, X., Nandakumar, S., Kundra, R., Lee, C. J., Schultz, N. D., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2438 · Cited by 33
Mortenson, K. L., Dawes, C., Wilson, E. R., Patchen, N. E., Johnson, H. E., Gertz, J., Bailey, S. D., Yang, J., Varley, K. E., & Zhang, X. (2024) · Nature Communications · doi:10.1038/s41467-024-50387-w · Cited by 35
Metadata
- Authors
- Takeda, D. Y., Spisák, S., Seo, J.-H., Bell, C., O’Connor, E., Korthauer, K., Ribli, D., Csabai, I., Solymosi, N., Szállási, Z., Stillman, D. R., Cejas, P., Qiu, X., Long, H. W., Tisza, V., Nuzzo, P. V., Rohanizadegan, M., Pomerantz, M. M., Hahn, W. C., & Freedman, M. L.
- Affiliations
- Broad Institute (US)
- Dana-Farber Cancer Institute (US)
- Harvard University (US)
- Eötvös Loránd University (HU)
- University of Veterinary Medicine (HU)
- Semmelweis University (HU)
- Boston Children's Hospital (US)
- Corresponding author
- Freedman, Matthew L.
- ORCID
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2018-07
- Volume
- 174
- Issue
- 2
- Pages
- 422-432.e13
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC6046260
- OpenAlex
- W2808687910
- Cited by
- 317
- References
- 55
- Citations by year
- 2026: 14 · 2025: 31 · 2024: 44 · 2023: 47 · 2022: 41 · 2021: 54 · 2020: 44 · 2019: 32 · 2018: 10
- FWCI
- 26.37
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Prostate Cancer Foundation Challenge Award
- NIH (R01GM107427, R01CA193910, K08CA218530, R01HG005220, U01 CA176058)
- National Research, Development and Innovation Fund of Hungary Project (FIEK_16-1-2016-0005)
- Novo Nordisk Foundation Interdisciplinary Synergy Programme (NNF15OC0016584)
- European Social Fund (EFOP-3.6.3-VEKOP-16-2017-00005)
- Breast Cancer Research Foundation (BCRF-17-156)
- H.L. Snyder Medical Research Foundation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- androgen receptor, advanced prostate cancer, treatment resistance, enzalutamide resistance, non-coding regulatory elements, genome editing, epigenetic profiling, oncogenic drivers
- MeSH terms
- Gene Editing, Acetylation, Adult, Aged, Antineoplastic Agents, Benzamides, Cell Survival, Enhancer Elements, Genetic, Histones, Humans, Male, Middle Aged, Neoplasm Metastasis, Nitriles, Phenylthiohydantoin, Receptors, Androgen, DNA Methylation, Cell Line, Tumor, CRISPR-Cas Systems, Prostatic Neoplasms, Castration-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
